StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate

Investors and analysts concluded Regenxbio's positive data was not encouraging enough to pose a competitive threat to the developer of the first marketed DMD gene therapy, Sarepta Therapeutics, or to Solid Biosciences, whose DMD gene therapy candidate SGT-003 is in Phase III as well as Phase I/II trials. Even worse for Regenxbio, investors were jolted by its disclosure that the FDA had recommended the company conduct a randomized controlled trial to assess RGX-202 in DMD. The post StockWatch: Re...